Valneva (NASDAQ:VALN) Trading 11.1% Higher – Here’s Why

Valneva SE (NASDAQ:VALN)’s share price shot up 11.1% on Monday . The stock traded as high as $6.99 and last traded at $6.99. 7,533 shares traded hands during mid-day trading, a decline of 79% from the average session volume of 36,559 shares. The stock had previously closed at $6.29.

Analyst Ratings Changes

Several analysts have recently commented on VALN shares. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Valneva in a research report on Wednesday, April 9th. Guggenheim reduced their price objective on shares of Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, March 24th.

Valneva Price Performance

The stock has a market cap of $566.39 million, a price-to-earnings ratio of -53.62 and a beta of 1.85. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company’s fifty day moving average is $6.98 and its two-hundred day moving average is $5.62.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. As a group, research analysts predict that Valneva SE will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its stake in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after buying an additional 30,859 shares during the period. ABC Arbitrage SA acquired a new position in shares of Valneva during the fourth quarter worth $84,000. Finally, GAMMA Investing LLC purchased a new position in Valneva in the first quarter valued at $94,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.